Medincell hits 5-year high after South Korea approves co's schizophrenia treatment

Handok

11/09/2025 08:46

** Shares in Medincell MEDCL.PA are up around 3% to their highest price since April 2020 after the company's schizophrenia treatment UZEDY received regulatory approval in South Korea

** Medincell receives mid- to high-single digit royalties on all worldwide sales and remains eligible for up to $105 million of commercial milestones payments, the company said in a statement

** "On the Medincell side, the good commercial performance of Uzedy® should allow to significantly increase royalties received, with 26.7 million euros ($31.21 million) estimated for 2025/26," says Midcap Partners in a note

** Stock is at the top of SBF120 index .SBF120

($1 = 0.8555 euros)

 (Reporting by Clement Martinot)

 ((Clement.Martinot@thomsonreuters.com;))